What type of study is this?

December 8, 2025BloodOpen Access

Azacitidine monotherapy versus combination regimens as post-allogeneic transplantation maintenance in high-risk myeloid malignancies: A retrospective cohort Study

View Full Paper

Ask AI

Bookmark

Authors

YSYing ShenGuiyang Medical University PZPengyu ZhangTianjin University JWJin WangHuaibei Normal University

Discussion

Member takes

Implication

Retrospective cohort reveals comparable overall survival with azacitidine monotherapy and combination regimens in high-risk myeloid malignancies post-transplant, suggesting tailored maintenance.

Key Points

Monotherapy with azacitidine demonstrated non-inferior efficacy to combination regimens with comparable toxicity.
The 3-year overall survival was 84.4%, indicating strong outcomes in high-risk myeloid malignancies post-transplant.
Survival analyses confirmed no significant difference in relapse rates across treatment groups and highlighted the role of specific biomarkers.
These findings support the use of azacitidine as a foundational strategy for post-transplant maintenance therapy in selected patients.

Cite This Study

Shen et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e518 https://doi.org/10.1182/blood-2025-2499

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort reveals comparable overall survival with azacitidine monotherapy and combination regimens in high-risk myeloid malignancies post-transplant, suggesting tailored maintenance.

Azacitidine monotherapy versus combination regimens as post-allogeneic transplantation maintenance in high-risk myeloid malignancies: A retrospective cohort Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Azacitidine monotherapy versus combination regimens as post-allogeneic transplantation maintenance in high-risk myeloid malignancies: A retrospective cohort Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider